-
Optum Rx Ends Reauthorization for Many Chronic Disease Drugs
19 Mar 2025 18:04 GMT
… chronic treatment
Long-term drug effectiveness … , Orkambi, Pulmozyme, Alyftrek
Multiple sclerosis drugs: Mavenclad, Plegridy, Lemtrada, … Ampyra, Gilenya, Tecfidera, Tysabri, Zeposia, Tascenso ODT, Briumvi
Migraine drugs … services in Medicare Advantage plans. …
-
Epilepsy Drugs Market to Worth USD 10.9 Billion by 2032, Driven by Innovation & Rising Prevalence – SNS Insider
13 Feb 2025 11:15 GMT
… to treatments, advanced epilepsy medications are … , Invega)
• Teva Pharmaceuticals - (Copaxone, Lamotrigine) … Acorda Therapeutics - (Ampyra, Inbrija)
Regional Analysis … Drugs Market by Product
8. Epilepsy Drugs Market by Drugs Type
9. Epilepsy Drugs …
-
Spinal Cord Injury Treatment Market to Reach USD 11.28 Billion by 2032, Driven by Technological Advancements
31 Jan 2025 12:19 GMT
… Medicine Research)
• Acorda Therapeutics - (Ampyra for … medications from SCI patients, particularly the administration of advanced pharmaceuticals … . Food and Drug Administration (FDA) has approved … Cord Injury Treatment Market by Treatment Type
8 …
-
FTC says top three PBMs made $7.3 billion from marked up drug prices
16 Jan 2025 01:59 GMT
… commercial health plans and Medicare Part D prescription drug plans managed by … Drug Codes, which include the generic versions of Ampyra (used to treat multiple sclerosis … data on commercial and Medicare Part D prescription drug plan (PDP) enrollees, …
-
New FTC Report: PBMs Mark Up Specialty Generic Drugs
14 Jan 2025 22:57 GMT
… commercial health plans and Medicare Part D prescription drug plans managed by … generic versions of Ampyra, which is used to treat multiple sclerosis; Gleevec, which … provide to Formulary Watch, the Pharmaceutical Care Management Association said: “It …
-
FTC Releases Second Interim Staff Report on Prescription Drug Middlemen
14 Jan 2025 23:18 GMT
… a wide range of lifesaving drugs, including medications to treat heart disease … commercial health plans and Medicare Part D prescription drug plans managed by … Drug Codes, which include the generic versions of: Ampyra (used to treat multiple sclerosis …
-
FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs
15 Jan 2025 18:11 GMT
… revenue from markups on essential medications used to treat cancer, … practices that may inflate drug costs and harm independent pharmacies … generic drugs, including critical medications such as Ampyra, Gleevec, Sensipar, and Myfortic.
These drugs accounted …
-
Acorda Joins Growing Group of Biotechs Filing for Bankruptcy, Divests Assets to Merz
03 Apr 2024 12:43 GMT
… asset purchase agreement with German biotech Merz Therapeutics, which has … , including its FDA-approved drugs Inbrija (levodopa inhalation powder), Ampyra (dalfampiridine) and … supply of our medications to people with multiple sclerosis and Parkinson’s …
-
Acorda loses Nasdaq listing to cap biotech’s end
16 Apr 2024 16:27 GMT
… twilight zone. The biotech’s closure date is … drugs for neurological disorders. Inbrija (levodopa inhalation powder) and Ampyra … ability of patients with multiple sclerosis.
According to GlobalData’s … the parent company of Pharmaceutical Technology.
Access the …
-
Acorda seeks buyer as neurological drug sales fall
05 Apr 2024 00:30 GMT
… of the year. Merz Pharmaceuticals, of Frankfurt, German, … founded in 1995 by medical doctor Ron Cohen. It is … developed medicines that treat Parkinson’s disease and multiple sclerosis.
Ampyra, also … drug was undergoing clinical trials. The U.S. Food and Drug …